Excellence Backed by ExperienceInSightec Ltd is the pioneer and global leader in MR guided focused ultrasound technology. Founded in 1999 by GE Healthcare (then GE Medical Systems) and Elbit Medical Imaging its mission is to transform its MR guided Focused Ultrasound (MRgFUS) into a clinically viable technology.
Quick links:Press here to hear an interview on how InSightec got started
Press here to hear about InSightec's vision
Since then, InSightec has invested close to $200 million in research and development. The company holds over 90 patents with additional intellectual property pending. The company is headquartered in Tirat Carmel, Israel, near the port city of Haifa. It has US offices in Milwaukee, WI and Dallas, TX as well as offices in Europe and Asia.
MR guided focused ultrasound combines two well known technologies to create a new breakthrough therapy. High intensity focused ultrasound waves precisely heat and destroy targeted tissue, non-invasively combines with magnetic resonance imaging (MRI) which provides precision anatomical visualization, and real time thermal feedback for treatment monitoring and guidance.
- Incisionless (non-invasive) surgery without anesthesia
- Outpatient procedure (2-4 hours)
- Short recovery, low trauma & morbidity
- Patient returns to normal activity the next day
- Minimizes complications (infections, surgical adverse events, transfusions, etc.)
- No long term toxicity or dose accumulation – repeatable procedure
- Green surgery – no sterilization or biohazardous waste
The company has two main products: ExAblate® O.R. and ExAblate® Neuro. The system is made up of a patient table that docks to the GE MRI, a console, an equipment cabinet, transducers and cooling units.
ExAblate® O.R. is a platform for treating body applications. The system incorporates interchangeable cradles which contain the focused ultrasound transducer. ExAblate O.R. is FDA approved for the treatment of symptomatic uterine fibroids and for pain palliation of bone metastases for patients with no other alternative. Clinical trials in the US are underway for prostate cancer, bone metastases and uterine fibroids.
ExAblate® Neuro is under clinical investigation and not allowed for sale in the USA.
ExAblate received its first European CE mark in 2002 and FDA (US Food and Drug Administration) approval in 2004 for the treatment of symptomatic uterine fibroids. In June 2007, ExAblate received the CE Mark for pain palliation of bone tumors and, in June 2010, for adenomyosis. In 2012 ExAblate received its second FDA approval for pain palliation of bone metastases and ExAblate Neuro received the CE Mark for the treatment of neurological disorders such as Essential tremor, Parkinson's and Neuropathic pain. In 2013 the CE mark was extended to other painful bone indications including primary and secondary bone cancers as well as benign diseases such as facet joint pain and osteoid osteoma.
InSightec continues to innovate and conduct clinical research. Click here for ongoing clinical studies
*Under clinical research
**Please note that not all applications are approved around the world. Please consult your local representative and read the product labeling specific for your region to determine approved indications for use.
ExAblate has won several awards for innovation and its potential to help mankind including The Wall Street Journal Technology Innovation Award and the European Union’s IST grand prize. TIME magazine recently named Focused Ultrasound as “one of 50 best inventions.”
All of InSightec’s products may be covered by one or more U.S. or foreign pending or issued patent
Treatment centers and clinical partners
There are over 100 ExAblate systems installed. InSightec has established clinical collaborations with leading hospitals and medical research institutions around the world. Many of these sites participate in sponsored trials to gather clinical data that will advance the company’s technology and create an ever-widening spectrum of clinical applications.
InSightec Ltd. is a privately held company and owned by Elbit Imaging, Elbit Medical Technologies, General Electric, MediTech Advisors LLC and employees.